Related Experiment Video
Updated: Aug 12, 2026
08:18
In Vitro Generation of Murine Plasmacytoid Dendritic Cells from Common Lymphoid Progenitors using the AC-6 Feeder System
Published on: November 23, 2015
In vivo generation of human dendritic cell subsets by Flt3 ligand
E Maraskovsky1, E Daro, E Roux
1Immunex Corporation, Seattle, WA, USA. eugene.maraskovsky@ludwig.edu.au
Blood
|July 27, 2000
Summary
Human Flt3 ligand (FL) significantly expands circulating dendritic cells (DCs) and their precursors in healthy volunteers. These expanded DCs are potent stimulators of T-cell immunity in vitro.
Area of Science:
- Immunology
- Cell Biology
Background:
- Dendritic cells (DCs) are crucial leukocytes regulating immune responses.
- DCs are utilized in immunotherapy vaccines due to their T-cell stimulation capabilities.
- The representativeness of in vitro-generated DCs compared to in vivo-developed DCs remains unclear.
Purpose of the Study:
- To investigate the effect of human Flt3 ligand (FL) on circulating dendritic cells (DCs) in vivo.
- To assess the functional capacity of FL-expanded DCs in stimulating T cells.
Main Methods:
- Administration of human Flt3 ligand (FL) to healthy human volunteers.
- Quantification of circulating CD11c(+) DCs and CD11c(-) IL-3Ralpha(high) DC precursors.
- In vitro assessment of T-cell stimulation by expanded CD11c(+) DCs.
Main Results:
- FL administration led to a substantial increase in circulating CD11c(+) DCs (mean 44-fold) and DC precursors (mean 12-fold).
- The expanded CD11c(+) DCs demonstrated efficient T-cell stimulation in vitro.
Conclusions:
- Flt3 ligand (FL) effectively expands the population of circulating human dendritic cells (DCs) in vivo.
- FL-expanded DCs are functionally competent and capable of stimulating T cells, suggesting potential therapeutic applications.
